Decisions / 4588
final resolution2020-12-03active

Arzneimittel-​​​Richtlinie/Anlage XII: Mogamulizumab (Mycosis fungoides, Sézary-Syndrom)

Open official decision page ↗

G-BA source · retrieved 2026-08-05

Structured conclusion

Final result by patient group

1 source-verified result

Patient group

Erwachsene Patienten mit Mycosis fungoides (MF) oder Sézary-Syndrom (SS), die mindestens eine vorherige systemische Therapie erhalten haben

Hint of non quantifiable added benefit

Comparator

Open official result PDF ↗

Decision orientation

What the G-BA did

4 cited claims

Each claim links to the official G-BA page or an exact PDF page range.

Official metadata

Decision date
2020-12-03
Effective
03.12.2020
Action type
final resolution
Committee
Arzneimittel

Case context

Listed normative targets

directiveArzneimittel-Richtlinie
directive annexAnlage XII: Nutzenbewertung nach § 35a SGB V

A listed target is not treated as a new directive version unless an official version source exists.

Official document package